• Vaccine Name: ALVAC-EIV (equine influenza virus H3N8)
• Target Pathogen: Influenza virus
• Target Disease: Influenza (flu)
• Vaccine Ontology ID: VO_0004735
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• hemagglutinin gene engineering:
  • Type: Recombinant protein preparation
  • Description: A new live recombinant vaccine derived from the canarypox virus vector and expressing haemagglutinin genes of EIV (subtype H3N8) (Paillot et al., 2006).
  • Detailed Gene Information: Click Here.
• Vector:
  • Vector name:
  • VO vector ID: VO_0001043
• Preparation: Live recombinant vaccine derived from the canarypox virus vector and expressing haemagglutinin genes of EIV (subtype H3N8) (Paillot et al., 2006).
• Immunization Route: Intramuscular injection (i.m.)

Horse Response

• Vaccination Protocol: The vaccine used in this study contained 10^5.6 FAID50 of both recombinants (defined as the minimum protective dose by the manufacturer). The vaccine was reconstituted with 2 ml of diluent containing Carbomer 974P just before use and injected intramuscularly into 12 ponies. Twelve control ponies were immunised with 2 ml of the Carbomer 974P diluent alone. Ponies were vaccinated on days 0 and 36 (Paillot et al., 2006).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: Each pony was challenged on day 50 (14 days after the second immunisation) by exposure to an aerosol generated from 20 ml of allantoic fluid containing around 10^7.3 50% egg infectious doses (EID50) of influenza (Paillot et al., 2006).
• Efficacy: Both incidence and duration of moderate/severe disease were statistically significantly reduced in the vaccinated horses as compared to the control horses. All 12 control ponies shed virus for a mean of 4.9 ± 1 days. None of the vaccinates shed virus after challenge infection (Paillot et al., 2006).